These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25299349)

  • 1. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
    Ohta H; Hamaya E; Taketsuna M; Sowa H
    Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.
    Yoh K; Hamaya E; Urushihara H; Iikuni N; Yamamoto T; Taketsuna M; Miyauchi A; Sowa H; Tanaka K
    Curr Med Res Opin; 2012 Nov; 28(11):1757-66. PubMed ID: 23035693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis.
    Urushihara H; Yoh K; Hamaya E; Taketsuna M; Tanaka K
    Health Qual Life Outcomes; 2014 Dec; 12():178. PubMed ID: 25495650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
    Takeuchi Y; Hamaya E; Taketsuna M; Sowa H
    Menopause; 2015 Oct; 22(10):1134-7. PubMed ID: 25756692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan.
    Hagino H; Soen S; Sugimoto T; Endo N; Okazaki R; Tanaka K; Nakamura T
    J Bone Miner Metab; 2019 Mar; 37(2):273-281. PubMed ID: 29523963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
    Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C; Herrero-Beaumont G; Acebes JC; Torrijos A; Graña J; Miguélez R; Sacristán J; Marín F
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I; Hattori S; Tanaka Y; Iwaoki Y
    J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate improves QOL of postmenopausal women with osteoporosis.
    Kawate H; Ohnaka K; Adachi M; Kono S; Ikematsu H; Matsuo H; Higuchi K; Takayama T; Takayanagi R
    Clin Interv Aging; 2010 Apr; 5():123-31. PubMed ID: 20458350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.
    Hongo M; Miyakoshi N; Kasukawa Y; Ishikawa Y; Shimada Y
    J Bone Miner Metab; 2015 Jul; 33(4):432-9. PubMed ID: 25123562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.
    Pelayo I; Haya J; De la Cruz JJ; Seco C; Bugella JI; Diaz JL; Bajo JM; Repolles M
    Menopause; 2008; 15(6):1132-8. PubMed ID: 18791486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
    Wermers RA; Recknor CP; Cosman F; Xie L; Glass EV; Krege JH
    Osteoporos Int; 2008 Jul; 19(7):1055-65. PubMed ID: 18283386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
    Scharla S; Oertel H; Helsberg K; Kessler F; Langer F; Nickelsen T
    Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
    Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
    Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
    Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
    Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.